Rolf Jautelat

Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents

Carbamoylsulphoximides as protein kinase inhibitors

Sulphimides as protein kinase inhibitors

CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents

CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents

CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents

Compound and a composition including such a compound

Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments

N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents

17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS

17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations

Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents

4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity